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Abstract
Background: The absence of rapid tests evaluating antibiotic susceptibility results in the empirical prescription of
antibiotics. This can lead to treatment failures due to escalating antibiotic resistance, and also furthers the
emergence of drug-resistant bacteria. This study reports a rapid optical method to detect β-lactamase and thereby
assess activity of β-lactam antibiotics, which could provide an approach for targeted prescription of antibiotics. The
methodology is centred on a fluorescence quenching based probe (β-LEAF – β-Lactamase Enzyme Activated
Fluorophore) that mimics the structure of β-lactam antibiotics.
Results: The β-LEAF assay was performed for rapid determination of β-lactamase production and activity of
β-lactam antibiotic (cefazolin) on a panel of Staphylococcus aureus ATCC strains and clinical isolates. Four of the
clinical isolates were determined to be lactamase producers, with the capacity to inactivate cefazolin, out of the
twenty-five isolates tested. These results were compared against gold standard methods, nitrocefin disk test for
β-lactamase detection and disk diffusion for antibiotic susceptibility, showing results to be largely consistent.
Furthermore, in the sub-set of β-lactamase producers, it was demonstrated and validated that multiple antibiotics
(cefazolin, cefoxitin, cefepime) could be assessed simultaneously to predict the antibiotic that would be most active for
a given bacterial isolate.
Conclusions: The study establishes the rapid β-LEAF assay for β-lactamase detection and prediction of antibiotic
activity using S. aureus clinical isolates. Although the focus in the current study is β-lactamase-based resistance, the
overall approach represents a broad diagnostic platform. In the long-term, these studies form the basis for the
development of assays utilizing a broader variety of targets, pathogens and drugs.
Keywords: Fluorescence, Fluorophore, Quenching, Staphylococcus, Cephalosporin, Cefazolin, β-lactamase, β-lactam,
Antibiotic activity, Antibiotic susceptibility
Background
Bacterial drug resistance is a growing global health chal-
lenge. Resistant infections are difficult to treat, tend to
spread relatively rapidly and increase healthcare costs
significantly [1]. Empiric antibiotic therapy is commonly
started before the results of antimicrobial susceptibility
testing (AST) are available. This is mainly because the
available AST methods are slow, typically requiring 24–
72 hours, being primarily based on bacterial growth.
Inappropriate empiric antibiotic regimens can be associ-
ated with treatment failures/prolonged illness [2,3], and
may also serve to promote resistant bacterial strains
[4-7]. Pre-prescription AST, such as rapid point-of-care
diagnostics, that can help identify the most effective
antibiotic for bacterial infections would be advantageous,
especially in the context of escalating resistance [8-10].
Bacterial antibiotic resistance can be due to a variety
of mechanisms, including enzymatic inactivation of anti-
biotics, altered target sites, decreased uptake and/or
increased efflux of the antimicrobial agents [11]. Mul-
tiple resistance factors can be present simultaneously
[12,13]. β-lactamases are a major antibiotic resistance
mechanism against the widely used β-lactam antibiotics,
which target penicillin-binding proteins (PBPs) involved
in bacterial cell wall synthesis [14]. β-lactamase enzymes
inactivate β-lactam antibiotics, by hydrolyzing their
β-lactam ring essential to antibiotic function [15,16].
There is a wide array of β-lactamases with varying
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has clinical significance [16-18]. Notably, many of the
‘ESKAPE’ pathogens (Enterococcus faecium, Staphylococcus
aureus, Klebsiella pneumonia, Acinetobacter baumanni,
Pseudomonas aeruginosa and Enterobacter species), respon-
sible for a majority of nosocomial infections [19], may pro-
duce β-lactamases.
Alongside the ever-growing threat of Methicillin Re-
sistant S. aureus (MRSA), Methicillin Susceptible S. aur-
eus (MSSA) strains are also highly prevalent and
responsible for severe infections such as infective endo-
carditis [20,21]. Both MRSA and MSSA can produce β-
lactamases [22-25]. Though by historical definition,
expression of an altered target penicillin binding protein
PBP2’ with lowered affinity for β-lactam antibiotics re-
sults in methicillin resistance [26-28], β-lactamase alone
may be responsible for borderline methicillin/oxacillin
resistance phenotype even in strains without PBP2’ [29].
Most MRSA strains produce β-lactamase in addition to
PBP2’ [22-24]. Among MSSA, ~90% strains are β-lactamase
producers [30].
β-lactamases can therefore present a challenge to suc-
cessful anti-bacterial therapy, in particular where the
bacterial burden is high. Cephalosporins are the treat-
ment of choice for MSSA infections [31-33]. Although
traditionally cephalosporins were believed to be stable to
the S. aureus β-lactamases, an ‘inoculum effect’ has been
demonstrated, wherein at high inocula some cephalo-
sporins get hydrolysed by β-lactamases [34,35]. The in-
oculum effect with different cephalosporins has been
reported in clinical isolates of MSSA [33,36], and in-
stances of clinical failure of cephalosporins are well doc-
umented in high-inoculum staphylococcal endocarditis
infections and bacteremia [37-40]. The inoculum effect
is not limited to Staphylococcus, and is observed in other
bacteria including Enterobacteriaceae, Pseudomonas and
Neisseria gonorrhoeae, with antibiotic classes other than
cephalosporins as well [35].
Evaluation of antibiotic susceptibility and detection of
resistance are mainly performed by means of disk diffu-
sion assays or broth/agar dilution to determine minimum
inhibitory concentration (MIC=lowest concentration of
antibiotic that inhibits the bacterial growth), where bac-
teria are cultured in the presence of antimicrobials and re-
spective growth patterns observed [41,42]. Besides agar or
broth dilution, the E-test is a relatively new, yet established
method for MIC determination, and consists of a prede-
fined gradient of antibiotic concentrations on a plastic
strip (www.biomerieux-diagnostics.com). The strips are
placed on inoculated agar plates and read following incu-
bation, in a manner similar to the disk-diffusion procedure
([43], www.biomerieux-diagnostics.com). For all of these
tests, based on the results obtained, the bacteria are classi-
fied as susceptible, intermediate or resistant to the tested
antimicrobial agent using breakpoints, i.e. threshold values
put forth by the Clinical and Laboratory Standards Insti-
tute (CLSI) or other regulatory authorities [41,42]. These
methods rely on growth of bacteria, hence are time-
consuming and unable to provide information to guide
antibiotic administration until about 24 h after a pathogen
has been isolated. They may also prove to be imprecise in
antibiotic susceptibility prediction in case of resistant bac-
teria, especially in context of β-lactamase producers
[44,45]. This is because even if the presence of a resistance
factor results in altered MICs or disk diffusion diameters,
interpretation can remain unaffected, as breakpoints may
not be reached [46,47]. To address this issue, the CLSI
regularly puts forth revised breakpoints and updates and
often recommends additional testing, such as determin-
ation of specific resistance mechanisms (e.g. β-lactamase
production) [41,42]. Also at times repeated testing may be
needed, such as in cases of serious infections requiring
penicillin therapy, the CLSI guidelines recommend
repeated MIC and β-lactamase testing on all subse-
quent isolates from patients [41,48]. Given these chal-
lenges, new methodologies that can provide timely
bacterial resistance and/or antibiotic susceptibility infor-
mation, such as that developed in our study, would be
valuable.
I nt h i ss t u d yw ed e s c r i b ear a p i do p t i c a lm e t h o d
(~60 min) for β-lactamase detection and assessing activity of
β-lactam antibiotics in presence of respective β-lactamase
(β-lactamase based antibiotic activity). The antibiotic activity
m a ya l s ob ei n t e r p r e t e dm o r eb r o a d l ya sa n t i b i o t i cs u s c e p t i -
bility (β-lactamase based antibiotic susceptibility). We have
developed a fluorescent molecular probe β-LEAF [β-Lacta-
mase Enzyme Activated Fluorophore (described as β-LEAP
in earlier publications)], based on fluorophore quenching-
dequenching, for rapid detection and characterization of
β-lactamases [49,50]. Although β-lactamase is widely
employed as a reporter system for gene expression using
fluorescent probes ([51-54] and (www.invitrogen.com)), this
approach is novel in that it also incorporates assessment to
predict the most active β-lactam antibiotic among tested
antibiotics, against given bacteria. In a previous report we
demonstrated the principle using ATCC strains with known
β-lactamase production for rapid functional definition of
Extended Spectrum β-Lactamases [50]. In the current study
we tested the approach with a panel of MSSA clinical iso-
lates, to determine β-lactamase production and predict the
activity of tested β-lactam antibiotic(s), in a rapid assay. The
concept behind the β-LEAF assay is illustrated in Figure 1.
The prototype β-LEAF construct mimics the structure of
β-lactam antibiotics. It contains a cephalosporin (β-lactam)
core structure, including a cleavable lactam ring, conju-
gated to two identical fluorophore (EtNBS) moieties [49].
The two fluorophores flanking the cephalosporin core are
in close apposition in the intact probe, which results in
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detected by an increase in fluorescence over time as
the enzyme cleaves β-LEAF to generate dequenched fluor-
ophores (Figure 1). When present together, an excess
β-lactam antibiotic and β-LEAF compete for the
β-lactamase enzyme due to structural similarity, leading
to reduced β-LEAF cleavage rate and thus reduced fluor-
escence change rate, compared to when β-LEAF is present
alone (Figure 1B). The reduction in fluorescence provides
insight into activity of the tested β-lactam antibiotic in the
presence of β-lactamase (β-lactamase-based antibiotic
activity). The read-out for the assay is optical (fluores-
cence), rather than bacterial viability or based on growth
of bacteria. We performed the assays with S. aureus clin-
ical isolates and cephalosporin antibiotics and validated
the results against standard methodologies for β-
lactamase and antibiotic susceptibility determination using
nitrocefin disk tests and disk diffusion or E-tests respect-
ively. Furthermore, we showed simultaneous testing of
multiple antibiotics, to help predict the most suitable anti-
biotic that could be used for therapy. Though validation in
a large number of isolates is needed to establish the
robustness of the assay, the initial results in a sample set
are encouraging, especially because the method is ~20
times faster than conventional methods. The β-LEAF
assay demonstrates the use of fluorescent substrates to
rapidly characterize resistance and predict antibiotic activ-
ity, and represents the first step towards the development
of a broader diagnostic platform.
Methods
Reagents, bacterial strains and culture conditions
Brain Heart Infusion (BHI) broth and BHI agar were ob-
tained from BD Difco (BD: Becton, Dickinson and Com-
pany, New Jersey, USA). Penicillin disks (10U), cefazolin
disks (30 μg), Mueller-Hinton II agar plates for suscepti-
bility testing by agar disk diffusion and cefinase disks
(nitrocefin disks) for detection of β-lactamase were pur-
chased from BD BBL. Cefoxitin and cefazolin E-test
strips were purchased from bioMerieux (Marcy l’Etoile,
France). Cefazolin-sodium and cefoxitin-sodium (powder
form) and cefepime-HCl (powder form) were obtained
from Novaplus (Novation, Texas, USA) and Sagent Phar-
maceuticals (Schaumburg, Illinois, USA) respectively. S.
aureus strains used in this study were purchased from
ATCC (Manassas, Virginia, USA) and clinical isolates
were provided by Dr. M.J. Ferraro (Microbiology Labs,
Massachusetts General Hospital, Boston, MA, USA)
(Table 1). All strains were routinely cultured in BHI agar
or broth at 37°C. The isolates were grown in presence of
penicillin disks to induce and enhance β-lactamase pro-
duction as required. For the disk diffusion assays,
Mueller-Hinton II agar plates were incubated at 35°C.
β-LEAF synthesis
β-LEAF was synthesized as previously described [49].
Briefly, the chloro- group on 7-amino-3-chloromethyl-3-
cephem-4-carboxylic acid p-methoxybenzyl ester (ACLE)
was substituted with 4-aminothiophenol with the help
Figure 1 Schematic showing the principle of the β-LEAF assay. A. The β-LEAF probe comprises a β-lactam core structure including the
cleavable lactam ring (green), flanked by two fluorophores (encircled), which undergo static quenching when the probe is intact. Following
cleavage by β-lactamase, the fluorophores move apart and show fluorescence. B. Assay profile for β-lactamase producing bacteria C. Assay profile
for lactamase non-producing bacteria.
Khan et al. BMC Microbiology 2014, 14:84 Page 3 of 14
http://www.biomedcentral.com/1471-2180/14/84of 4-methylmorpholine. The purified product was
mixed with 5-(4′-carboxybutylamino)-9-diethylamino-
benzo[a]phenothiazinium chloride (EtNBS-COOH), O–
(7-azabenzotriazole-1-yl)-N,N,N,N’-tetramethyluronium-
hexafluorophosphate(HATU), and diisopropylethylamine
in dry N,N-dimethylformamide. The reaction mixture was
stirred at room temperature for 3 h then purified on silica
coated preparative thin-layer chromatography. After re-
moval of the p-methoxybenzyl protection group, Reversed
Phase-High Performance Liquid Chromatography was
performed to yield β-LEAF in high purity (>95%). Con-
centrated stocks were prepared in 100% DMSO and
stored at −20°C.
β-LEAF- antibiotic fluorescence assay
Bacterial strains were cultured on BHI agar plates in the
presence of a penicillin disk (10U) overnight. For each
bacterial isolate, colonies closest to the penicillin disk were
transferred to PBS to make a homogenous suspension
[~10
9 Colony Forming Units (CFU)/ml]. Bacterial O.D.
was measured at 600 nm. 100 mM antibiotic solution (4X
stock) was prepared by dissolving the antibiotic powder in
PBS, and 20 μM β-LEAF probe solution (2X stock) was
prepared in 40% DMSO in PBS. The assays were per-
formed in 96-well white clear-bottom plates in a total vol-
ume of 100 μl respectively, to include bacteria and 10 μM
β-LEAF probe, with or without 25 mM antibiotic (cefazo-
lin). Each reaction was set up as follows: 25 μlb a c t e r i a l
suspension, 25 μl antibiotic 4X stock solution or PBS only
and 50 μl probe 2X stock solution, with resultant buffer
concentration as 20% DMSO in PBS in each 100 μlr e a c -
tion. For each isolate, reactions were performed in tripli-
cate in the absence and presence of test antibiotic
respectively. Time course assays were carried out, moni-
toring β-LEAF cleavage by measuring fluorescence for
60 min, at 1 min intervals (Spectramax M5 Plate Reader,
Molecular Devices). Instrument settings were kept as exci-
tation 640 nm, emission 700 nm and temperature was
maintained at 37°C throughout. β-LEAF cleavage rate in
each case was determined as slope i.e. fluorescence change
as a function of time (obtained from instrument software
- SoftMax Pro5), normalized by bacterial O.D.
For multiple antibiotic testing, reactions were similarly
set up with β-LEAF only, and with β-LEAF and cefazo-
lin, cefoxitin or cefepime in separate reactions.
S. aureus ATCC strains with established β-lactamase
status, β-lactamase producing strain 29213 (#1), and β-
lactamase negative strain 25923 (#2), were used as posi-
tive and negative control strains respectively in all assay
sets. Bacteria-free controls (PBS only) were also included
in each assay set.
For ‘un-induced’ growth cultures, bacterial strains/
isolates were cultured on non-selective BHI agar
plates, with the rest of the protocol remaining un-
changed.
Nitrocefin disk test for detection of β-lactamase
The experiments were performed using cefinase disks
(nitrocefin disks) as per manufacturer’s recommendations.
Table 1 S. aureus isolates used in the study and their
β-lactamase genotype and phenotype
# S. aureus
isolate
β-lactamase
genotype*
&
(‘blaZ’ PCR)
β-lactamase
phenotype by
nitrocefin disk test
1 29213 Positive +
2 25923 Negative -
3 75391-09 Positive -
4 W5337 Negative -
5 W53156 Positive -
6 AI5070237 Positive +
7 AI5081845 Positive -
8 159570-08 Positive -
9 H30876 Positive -
10 32455-09 Positive
$ -
11 HIP12052 Positive -
12 AI5090298 Positive -
13 F33263-2 Positive -
14 AI5090297 Positive -
15 HIP11033 Positive -
16 HIP11353 Positive
$ -
17 158390-08 Positive
$ -
18 F52670 Positive +
19 H63189 Positive +
20 M24125 Positive +
21 F20358.1 Negative -
22 H67147.3 Positive -
23 M60028 Negative -
24 KI58249.2 Unknown -
25 M69678 Negative -
26 X33116 Positive -
27 F29916-2 Positive -
S. aureus strains 29213 (#1) and 25923 (#2) were obtained from ATCC and the
S. aureus clinical isolates (#3 - #27) were provided by Dr. Mary Jane Ferraro
(Microbiology Labs, Massachusetts General Hospital, Boston, MA, USA). Isolate
numbers (e.g. #1 for 29213, etc) are used to refer to the different isolates
throughout the study.
*The β-lactamase genotype was determined by PCR to detect blaZ (staphylococcal
β-lactamase gene). Genotype data for isolates #3 - #15 was kindly provided by
Dr. Robert L. Skov, Statens Serum Institut (R. L. Skov, unpublished results) and
for #16 - #27 by Dr. Mary Jane Ferraro.
&All isolates are MSSA.
$Special comment – blaZ contained Stop codon or deletion (so non-functional)
(R. L. Skov, unpublished results).
Nitrocefin disk test to determine β-lactamase production was performed as
described in Methods. Development of orange colour uniformly, similar to
positive control #1, was taken as positive reaction, indicated by ‘+’ symbols.
‘-’ denotes negative result (i.e. no colour change). The results are representative
of three independent experiments, which gave consistent results.
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ence of penicillin disks (to induce and enhance β-
lactamase production) respectively were used. For each
isolate, the nitrocefin disks were moistened with ddH2O,
and colonies that grew closest to the penicillin disk were
smeared evenly across the nitrocefin disk surface using an
inoculating loop. Disks were observed for colour change
up to 60 min. β-lactamase producer strain ATCC 29213
(#1) and β-lactamase negative strain ATCC 25923 (#2),
were used as positive and negative controls respectively.
Antibiotic susceptibility testing - disk diffusion and E-test
The standard procedure recommended by CLSI was
followed [41,42]. Briefly, inoculum was prepared by the
direct colony suspension method preferred for S. aureus.
Isolated colonies from non-selective overnight BHI agar
plates were used to make a saline suspension, and tur-
bidity was adjusted equivalent to a 0.5 McFarland tur-
bidity standard. Thereafter, the standardized inoculum
was spread uniformly on a Mueller Hinton II agar plate,
allowed to dry, cefazolin disk applied to the centre of the
plate, and plates incubated at 35°C for 20–24 h. The zones
of inhibition were measured and compared against CLSI
Zone Diameter Interpretive Charts, to categorize isolates
as susceptible, intermediate or resistant. (The CLSI 2012
charts were used, which were most current at the time of
the experiments [41]). S. aureus ATCC 25923 (#2) was in-
cluded in each experiment as the CLSI recommended
quality control strain for disk diffusion [41].
For the zone edge test comparison criteria, ATCC
29213 (#1) and ATCC 25923 (#2) were used as the CLSI
recommended positive and negative controls, showing
‘sharp’ and ‘fuzzy’ inhibition zone edges respectively.
For the E-test, cefoxitin or cefepime E-test strip was
applied to the inoculated plate, and following incubation
at 35°C for 24 h, the MIC value was read. The CLSI in-
terpretive criteria, most current at the time of experi-
ments, were used to categorize isolates as susceptible,
intermediate or resistant [41]. S. aureus ATCC 29213
(#1) was included in each experiment as the recom-
mended quality control for MIC determination [41].
Experiments were similarly performed with ‘induced’
growth cultures, wherein bacteria grown in presence of
penicillin disks overnight were used as the starting in-
oculum to prepare the saline suspension. The standard
procedure described above was followed.
Results
β-LEAF assays determine β-lactamase production and
assess cefazolin activity
We used a panel of S. aureus comprising two ATCC
strains and 25 clinical isolates (Table 1) as a model system.
Isolate numbers (eg. #1, #4, etc.), rather than full names,
are used to refer to isolates as per Table 1 throughout this
study. ATCC strains with established β-lactamase status,
β-lactamase producing strain 29213 (#1) and β-lactamase
negative strain 25923 (#2) were used as positive and nega-
tive controls respectively. Cefazolin, a first generation
cephalosporin, was used as the test antibiotic in these ex-
periments. Each isolate was assayed under two conditions,
with β-LEAF alone and with β-LEAF and saturating con-
centration of cefazolin (2500-fold higher concentration of
cefazolin than β-LEAF) respectively.
Distinct fluorescence profiles were observed for the
control strains #1 and #2 (Figure 2). When assayed only
in the presence of β-LEAF, a significant increase in fluor-
escence was observed with the β-lactamase producer
strain #1. However, when the assay included both β-
LEAF and cefazolin, a drastically lower β-LEAF cleavage
rate (as measured by fluorescence change over time) was
seen (Figure 2). Strain #2 does not encode β-lactamase
and showed low fluorescence in both the β-LEAF alone
and β-LEAF +cefazolin reactions (Figure 2).
The various clinical isolates showed different patterns
of fluorescence, and were categorized by comparing
with the profile of the control strains. When assayed
with β-LEAF alone, isolates #6, #18, #19 and #20
showed appreciable β-LEAF cleavage rates similar to
that observed for #1 (Figure 2), and were designated as
β-lactamase producing strains. These also showed sig-
nificantly lower cleavage rates when the assay was per-
formed with both β-LEAF and cefazolin (Figure 2).
Testing with several-fold higher concentration of the
antibiotic compared to probe concentration (as per
assay design) increases chances of the antibiotic becom-
ing the preferred substrate for the respective lactamase
enzyme. The corresponding decrease in β-LEAF cleav-
age in the presence of the antibiotic, compared to when
β-LEAF is present alone i.e., reduction in fluorescence
due to competition (Figure 1), is used to predict activity
of the antibiotic (reduction in fluorescence is inversely
proportional to its predicted activity in presence of a
lactamase). For isolates #6, #18, #19 and #20, the dras-
tically reduced probe cleavage rates (in presence of the
antibiotic) indicated that cefazolin was capable of com-
peting against the β-LEAF for enzyme binding, and
likely to be a substrate of the β-lactamase in these iso-
lates. Hence, cefazolin may be readily inactivated by the
respective lactamases produced by these isolates. All
other isolates showed fluorescence profiles similar to
#2. Although, ideally #2 should not exhibit fluorescence
change over time, a slight increase was noted (Figure 2).
A range of mean ±3X standard deviation observed for
#2 (β-LEAF only reaction) would give 99.7% confidence
intervals for values by Gaussian statistics. The upper
limit of this range, i.e. mean+3X standard deviation
was set up as a cut-off value (Figure 2). Isolates showing
cleavage rates within this cut-off, that is, low/negligible
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non-producer #2, were designated as non-producers of
β-lactamase. Also as negligible differences between the
cleavage rates of β-LEAF and β-LEAF+cefazolin reac-
tions were observed, cefazolin was predicted to be active
to treat infections caused by these bacteria. Isolates that
showed cleavage rate of β-LEAF alone higher than the cut-
off included those observed to cleave β-LEAF efficiently
(#6, #18, #19 and #20), as well as some isolates showing
marginal differences from #2, such as #22. These could be
low producers. As the difference in cleavage rates in the
absence and presence of cefazolin was minimal in these
marginal cases, cefazolin was predicted as active. The re-
sults of the β-LEAF assay for all isolates are summarized
in Table 2 (column 2 and column 6).
Bacteria-free controls (PBS only) were included in
each assay-set to account for non-specific probe cleavage
that may occur. As expected, a negligible fluorescence
change over time was observed. Comparison of cleavage
rates (mRFU/min) for #1, #2 and the PBS only control
are shown in Additional file 1: Figure S1.
Nitrocefin test for detection of β-lactamase validates
results from β-LEAF assay
In order to validate the β-lactamase phenotypes deter-
mined by the β-LEAF assay, a CLSI recommended β-
lactamase screening method, the chromogenic nitrocefin
test, was utilized [41]. All bacterial isolates that were
strongly positive by the β-LEAF assay were also found to
be positive by nitrocefin conversion with the nitrocefin
disks, showing a change in colour from yellow to deep
orange in a positive reaction for β-lactamase (Table 1,
right-most column).
Comparison of conventional disk diffusion and β-LEAF
assay results
In order to compare predictions of cefazolin activity by the
β-LEAF assay to a conventional AST method, we performed
cefazolin disk diffusion assays with the S. aureus isolates.
Based on respective zone of inhibition diameters, each iso-
late was classified as susceptible, intermediate or resistant
using the CLSI zone interpretive criteria (Table 3, Additional
file 2: Figure S2). Interestingly, all the isolates fell in the cefa-
zolin ‘susceptible’ range with this methodology (Table 3).
To ascertain whether isolates producing detectable
amounts of β-lactamases would show altered disk diffu-
sion results, we performed disk-diffusion assays for the
predicted ‘cefazolin less active’ isolates (#1, #6, #18, #19,
#20) (Figure 2) of the β-LEAF assay using both ‘induced’
and ‘un-induced’ growth cultures as inoculum respect-
ively (conventional AST is usually performed using ‘un-
induced’ inoculums). This would also verify if observed
discrepancy in antibiotic activity/susceptibility prediction
between the β-LEAF assay and disk-diffusion was caused
by the different induction statuses (β-LEAF assay =in-
duced growth cultures, disk diffusion assays = standard
growth, see Methods). Using induced cultures as starting
inoculum, however, did not change the results of cefazo-
lin AST, compared to using standard (un-induced) in-
oculum (Additional file 3: Table S1).
β-lactamase detection is an important screening test,
and the zone edge test (using penicillin) has recently
been included in the CLSI guidelines for this purpose.
[41,42]. A sharply demarcated zone edge in disk diffu-
sion assays correlates well with β-lactamase production
[41,42,55]. Based on this criterion, a sharp zone edge for
isolates #1, #6, #18, #19, and #20 was seen, designating
them lactamase producers (Table 3, Additional file 2:
Figure 2 β-LEAF assays determine β-lactamase production and cefazolin activity in S. aureus clinical isolates. β-LEAF assays were performed
with two ATCC S. aureus control strains (known β-lactamase producer #1 and non-producer #2) and 25S. aureus clinical isolates, with cefazolin as a test
antibiotic. The different bacterial isolates were incubated with β-LEAF (probe) alone and β-LEAF and cefazolin respectively, and fluorescence was
monitored over 60 min. The y-axis represents the cleavage rate of β-LEAF (measured as fluorescence change rate – milliRFU/min) normalized by
bacterial O.D. (optical density) at 600 nm. The black bars depict cleavage rate when β-LEAF alone is used, to show β-lactamase production. The white
bars depict cleavage rate of probe when both the probe and cefazolin are included in the reactions. The horizontal line indicates a proposed cut-off
value (upper limit of mean±3X Std. deviation for strain #2, β-LEAF probe reaction) to demarcate β-lactamase production. Where the black and white
bars are significantly different, the antibiotic is predicted to be less active. Results are presented as the average of three independent experiments (each
experiment contained samples in triplicates) and error bars represent the standard error for all isolates, except #2. For #2, the error bar is 3X standard
deviation.
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‘cefazolin less active’ and lactamase producers using the
β-LEAF assay and nitrocefin tests (Figure 2, Table 1
(nitrocefin test results), Table 2). Thus, the disk-diffusion
test results on the whole, with results from cefazolin
susceptibility and zone edge tests taken together, corre-
sponded with the β-LEAF assay predictions, as by virtue
of β-lactamase production respective isolates may show
some degree of resistance to cefazolin.
Table 2 summarises comparison of results for β-
lactamase production (columns 2–4) and cefazolin
susceptibility/activity (columns 5–6), along with the β-
lactamase genotypes (column 1) for all isolates in the
study. Overall, the results from the rapid β-LEAF assay
Table 2 Comparison of different methods of β-lactamase detection and cefazolin antibiotic susceptibility/activity
determination
S. aureus
isolate #
β-LACTAMSE GENOTYPE
(‘blaZ’ PCR)
β-LACTAMASE PHENOTYPE CEFAZOLIN SUSCEPTIBILITY/ACTIVITY
β-LEAF
assay*
Nitrocefin disk test Zone edge test Disk diffusion Antibiotic activity –
β-LEAF assay**
‘+’=positive PCR Uniform orange
color=‘+’ (positive)
Sharp zone
edge= ‘+’ (positive)
S=susceptible LA= less active
$: contained stop
codon or deletion
(!) =sharp
zone edge
A= active
1 + + + + S (!) LA
2--- - SA
3+- - - S A
4-- - - S A
5+- - - S A
6 + + + + S (!) LA
7+- - - S A
8+- - - S A
9+- - - S A
10 +
$ -- - S A
11 + - - - S A
12 + - - - S A
13 + - - - S A
14 + - - - S A
15 + - - - S A
16 +
$ -- - S A
17 +
$ -- - S A
18 + + + + S (!) LA
19 + + + + S (!) LA
20 + + + + S (!) LA
21 - - - - S A
22 + (Weak) + - - S A
23 - - - - S A
24 Unknown - - - S A
25 - - - - S A
26 + - - - S A
27 + - - - S A
Col. 1 Col. 2 Col. 3 Col. 4 Col. 5 Col. 6
$Special comment – blaZ contained Stop codon or deletion (so non-functional) (Robert L. Skov, unpublished results).
*Classification into positive and negative is based on proposed cut-off depicted in Figure 2 (upper limit of mean ± 3X Std. deviation for strain #2, β-LEAF probe
reaction) to demarcate β-lactamase production. Isolates showing cleavage rates of β-LEAF (black bars in Figure 2) lower than or equal to the cut-off were designated
‘negative’, while isolates with higher cleavage rates were designated ‘positive’.
**Classification of cefazolin as ‘active’ or ‘less active’: When difference in cleavage rates (fluorescence change) in the absence and presence of cefazolin was
minimal, antibiotic predicted to be ‘active’. Drastically lowered cleavage rate in presence of cefazolin compared to when probe assayed alone led to prediction of
cefazolin as ‘less active’ respectively (also see Figure 2).
Details of Disk Diffusion results are presented in Table 3.
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validating the methodology. However, the presence of
the blaZ gene did not always correlate with a lactamase
positive phenotype.
Defining activity profiles for multiple antibiotics using
β-LEAF
The next set of investigations focussed on the β-LEAF
assay to test multiple antibiotics simultaneously, to help
predict the antibiotic activity profile for a particular bac-
terial isolate. For these studies we tested a sub-set of the
isolates, the ATCC control strains (#1 and #2) and four
isolates (#6, #18, #19, and #20) that produce appreciable
amounts of β-lactamase as per both the β-LEAF assay
and the nitrocefin test (Table 2). In addition to the first
generation cephalosporin cefazolin, we used cefoxitin
and cefepime, second and fourth generation cephalospo-
rins respectively. Notably, cefepime is known to be more
resistant to hydrolysis by β-lactamases [56,57]. In the β-
LEAF and cefazolin or cefoxitin reactions, fluorescence
was significantly reduced compared to β-LEAF alone re-
actions with all tested isolates (Figure 3). In contrast, for
cefepime+ β-LEAF reactions, the reduction in fluores-
cence was not as drastic as observed for the other two
antibiotics, being 50% or even less (Figure 3). This incom-
plete reduction indicated that cefepime failed to compete
efficiently with β-LEAF for the lactamase, despite its satur-
ating concentration. Following this, cefepime is least likely
to be inactivated by the β-lactamase, and thus predicted as
likely to be most active for treatment among the three an-
tibiotics tested. Bacteria-free (PBS only) control reactions
are presented in Additional file 1: Figure S1.
To simplify interpretation, we calculated a ratio of the
cleavage rate of β-LEAF in the presence of an antibiotic
to cleavage rate of β-LEAF alone, for each antibiotic, for
the different bacteria (Table 4). This ratio approaching
Table 3 Cefazolin disk diffusion results
S. aureus
isolate #
Zone of
inhibition
diameter (mm)
AS* Zone
edge
Interpretation
as per zone edge
test criteria
&
1 21.5±1.0 S Sharp β
2 31.0±1.0 S Fuzzy
3 33.5±0.5 S Fuzzy
4 33.0±2.0 S Fuzzy
5 32.5±0.5 S Fuzzy
6 36.5±0.5 S Sharp β
7 32.0±0.5 S Fuzzy
8 39.5±1.5 S Fuzzy
9 29.5±1.5 S Fuzzy
10 41.5±0.5 S Fuzzy
11 34.5±2.5 S Little fuzzy Weak β?
12 41.0±1.6 S Fuzzy
13 32.5±0.5 S Fuzzy
14 33.0±0.0 S Fuzzy
15 35.5±2.5 S Fuzzy
16 36.5±0.5 S Fuzzy
17 36.5±0.5 S Fuzzy
18 33.5±0.5 S Sharp β
19 31.0±0.0 S Sharp β
20 20.5±0.3 S Sharp β
21 38.0±1.0 S Fuzzy
22 34.0±1.1 S Little fuzzy Weak β?
23 33.5±1.5 S Fuzzy
24 34.5±1.5 S Fuzzy
25 30.5±0.5 S Fuzzy
26 34.0±0.0 S Fuzzy
27 36.0±2.0 S Little fuzzy/
sharpish
Weak β?
*The Antibiotic Susceptibility (AS) was determined using the CLSI Zone
Diameter Interpretive Criteria for Cefazolin Disk Diffusion [41].
≤ 14 mm: Resistant (R); 15–17 mm: Intermediate (I); ≥ 18 mm: Susceptible (S)
The results shown are averages of at least two independent experiments, and
are presented as Average± Standard Error. The CLSI recommended quality
control strain ATCC 25923 (#2) was included each time and gave zone of
inhibition diameter within the expected range (29-35 mm) [41].
&The zone edge test was also applied and the edge of the zone of inhibition
was observed. S. aureus ATCC 29213 (#1) was used as a positive control for the
zone edge test (sharp edge), and ATCC 25923 (#2) as a negative control (fuzzy
edge). ‘β’ denotes β-lactamase producing strain.
Figure 3 β-LEAF assays can be used to determine activity of
multiple antibiotics simultaneously. β-LEAF assays were set up
with multiple antibiotics (cefazolin, cefoxitin and cefepime) in
selected S. aureus isolates. Antibiotic activity was assessed in positive
control strain #1, negative control strain #2 and four S. aureus clinical
isolates that showed substantial β-lactamase production (#6, #18,
#19, #20). The different bacterial strains were incubated with β-LEAF
alone and β-LEAF and cefazolin/cefoxitin/cefepime respectively.
Fluorescence was monitored over 60 min. The y-axis represents
cleavage rate of β-LEAF (measured as fluorescence change rate –
milliRFU/min) normalized by bacterial O.D. (optical density) at
600 nm. Results are presented as the average of three independent
experiments (each experiment contained samples in triplicates) and
error bars represent the standard error.
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the bacterial isolate in context of β-lactamase based re-
sistance. Such an analysis is conceptually similar to the
breakpoints values put forth by the CLSI and other regu-
latory authorities [41,42], where bacteria are classified as
susceptible, intermediate or resistant to a given anti-
microbial agent. This ratio in our method is meaningful
only for isolates that produce significant amounts of β-
lactamase. For other isolates, the difference in values
when assayed with and without antibiotics respectively
are negligible, and the ratios may give exaggerated re-
sults, such as for strain #2 (Table 4) and other isolates
(data not shown). For such bacteria, the antibiotics may
be considered active with regards to β-lactamase based
resistance.
Comparison of E-test and β-LEAF assay results
Next, the antibiotic activity data for cefoxitin and cefe-
pime from the fluorescence based β-LEAF assay was
compared to antibiotic susceptibility determined using
E-tests. We utilized the E-test an alternate AST method
to determine antibiotic susceptibility conventionally. For
S. aureus, cefoxitin is used as an oxacillin surrogate, and
oxacillin resistance and cefoxitin resistance are equated
[41]. Applying these criteria, #1, #2 and #6 were pre-
dicted as cefoxitin susceptible, while #18, #19 and #20
were predicted to have different degrees of resistance to
cefoxitin (Table 5). However, #1, #6, #18, #19 and #20
were shown to be β-lactamase producers (Table 2, col-
umns 2, 3 and 4), with the β-LEAF assay indicating
cefoxitin to be less active (Figure 3, Table 4). All isolates
were predicted to be susceptible to cefepime (Table 5),
consistent with β-LEAF assay predictions, and with cefe-
pime being stable to β-lactamases.
Cefoxitin and cefepime MICs with induced growth
inoculum for these isolates were also determined
(Additional file 3: Tables S2 and S3). Though MICs were
marginally altered for some isolates with induced inocu-
lum compared to standard inoculum, the antibiotic
susceptibility interpretation was unaffected (Additional
file 3: Tables S2 and S3).
β-lactamase induction may not be necessary to perform
β-LEAF assays
We also compared the effectiveness of the β-LEAF assay
with induced growth cultures to un-induced cultures
(Additional file 4: Figure S3). Growth in the presence of
penicillin overnight serves to induce and enhance β-
lactamase production, but adds another step. Without
the induction step, the total turnover time from isolate
obtained to antibiotic activity prediction would be only
1 hour. β-lactamase was readily detected even without
induction, though at lower levels compared to induced
cultures for some isolates (Additional file 4: Figure S3).
Antibiotic susceptibility profiles were also similar for un-
induced and induced bacteria (Additional file 4: Figure S3).
As induction of lactamases may not be a pre-requisite for
performing the β-LEAF assay, this result shows promise
for extending the assay to rapid direct bio-specimen
testing.
Discussion
In order to combat bacterial infections effectively, the
rapid identification of appropriate treatment modalities
is critical [10]. Determination of antibiotic susceptibility
and resistance are key to this process [8,9]. This report
describes a rapid method to address these two aspects
by exploiting the property of fluorescence quenching-
dequenching. Although the sample numbers used in this
study are too small for this method to be viewed as a ro-
bust dual assay at this stage, the results are promising.
There are several mechanisms of bacterial resistance,
both inherent and acquired, and production of β-
lactamases, which enzymatically cleave and thereby
Table 4 Ratios from β-LEAF assays to assess activity of
tested antibiotics in context of β-lactamase resistance
S. aureus isolate
Antibiotic #1 #2* #6 #18 #19 #20
Cefazolin 0.11 0.55 0.08 0.13 0.12 0.36
Cefoxitin 0.11 0.64 0.09 0.12 0.12 0.30
Cefepime 0.68 0.44 0.80 0.58 0.47 0.66
Ratios were calculated as [Cleavage rate (β-LEAF + antibiotic)/Cleavage rate
(β-LEAF alone)] using data depicted in Figure 3, for each antibiotic for the
different bacteria tested, and rounded to two decimal points. Closer the value
to ‘1’, more active an antibiotic predicted to be for the respective bacterial
strain/isolate taking β-lactamase resistance into consideration.
NOTE: *For isolates that show low cleavage rates with β-LEAF (e.g. #2), there is
negligible difference in values when antibiotics are included in the reaction,
and the ratios may give exaggerated results. For such strains, the antibiotics
may be considered active/usable.
Table 5 Cefoxitin and Cefepime MIC (by E-test) for selected
bacterial isolates
S. aureus
isolate
Cefoxitin
MIC (μg/ml)
Cefoxitin
AS*
Cefepime
MIC (μg/ml)
Cefepime
AS**
#1 3.0±0.0 S 3.3±0.3 S
#2 2.2±0.4 S 1.7±0.3 S
#6 3.0±1.0 S 2.8±0.7 S
#18 4.0±1.0 I 2.0±0.5 S
#19 6.0±1.0 I 3.0±0.6 S
#20 20.0± 2.3 R 7.0±0.6 S
*The Cefoxitin Antibiotic Susceptibility (AS) was determined using the CLSI
Interpretive Criteria for cefoxitin as an oxacillin surrogate [41].
≤ 4 μg/ml - Susceptible (S), ≥ 8 μg/ml- Resistant (R), values in between Intermediate (I).
**The Cefepime Antibiotic Susceptibility (AS) was determined using the CLSI
Interpretive Criteria for cefepime [41].
≤ 8 μg/ml - Susceptible (S), 16 μg/ml - Intermediate (I), ≥ 32 μg/ml - Resistant (R)
The results are presented as an average of three independent experiments as
Average±Std. Error. The CLSI recommended quality control for MIC for S. aureus,
ATCC 29213 (#1) was included each time, and showed MIC within the expected
range for cefoxitin (1–4 μg/ml) and cefepime (1–4 μg/ml) respectively.
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antibiotic resistance and pathogen protection. The β-
LEAF assay presented here focuses on this resistance
mechanism. The strategy employs a molecular probe
that is quenched until cleaved by the β-lactamase en-
zyme, following which fluorophores are dequenched and
become fluorescent (Figure 1). The β-LEAF probe is de-
signed to mimic β-lactam antibiotics and is thus sensi-
tive to β-lactamases [49,50]. Owing to similarity in core
structures, a β-lactam antibiotic and β-LEAF compete
for the enzyme when present together [50]. The fluores-
cence readout therefore may report both presence of β-
lactamases and β-lactam antibiotic activity. The compe-
tition between the probe and the β-lactam antibiotic re-
sults in reduced probe cleavage and hence diminished
fluorescence, compared to when the probe is assayed
alone (Figure 1). Using several-fold higher concentra-
tions of the test β-lactam antibiotic, compared to the
probe, enhances the likelihood that the antibiotic will be
the preferred substrate of the lactamase in the competi-
tion reaction in the assay. The reduced fluorescence in-
directly reflects the ability of the β-lactamase to bind
and cleave the tested antibiotic (large difference = anti-
biotic can be readily bound and hence cleaved and inac-
tivated). Notably, unlike growth based conventional AST
methods, the end-point of the β-LEAF assay is not bacter-
ial viability or differences in growth pattern. The read-out
of the assay is fluorescence, which reflects probe cleavage
due to the enzymatic activity of the β-lactamase. Import-
antly, the β-LEAF assay is rapid compared to the conven-
tional growth based AST methods (1 h versus 20–24 h for
disk diffusion/MIC conventionally or ~8 h with auto-
mated instruments).
The observation in Figure 2 of low to negligible fluor-
escence in β-LEAF + cefazolin reactions with all β-
lactamase ‘positives’ (#1, #6, #18, #19, #20) suggests that
cefazolin can be readily targeted and inactivated by the
respective lactamases, and would be anticipated to be a
less effective treatment option for these bacteria. An ex-
pectation of this assay is that the reduction in probe
fluorescence in the presence of an antibiotic will be in-
versely proportional to its predicted activity against the
pathogen. If fluorescence is completely reduced in the
presence of an antibiotic, then the respective antibiotic
can be readily cleaved and inactivated by β-lactamase.
However, if despite the ‘saturating’ amount of antibiotic,
some fluorescence increase reflecting probe cleavage is
still observed (e.g. cefepime reactions in Figure 3), the
lactamase may not be capable of effectively destroying
the antibiotic, and the antibiotic predicted as likely to be
active. In experiments with multiple antibiotics (Figure 3)
a ratio of the cleavage rate of β-LEAF in presence of an
antibiotic to the cleavage rate of β-LEAF alone, for each
antibiotic tested, is shown in Table 4. For β-lactamase
based resistance, the ratio of cleavage rates closer to 1
(Table 4) would indicate greater β-lactam antibiotic effi-
cacy. With more rigorous testing from multiple data sets
on a large number of isolates, cut-offs could be set up to
develop the ratios as a ‘β-lactamase-based antibiotic
activity/susceptibility index’ within specific limits. We
recognize that there are a wide variety of lactamases,
and note that with appropriate kinetic analysis (such as
building on our previous study [50]), the approach pre-
sented here has the potential of characterizing the differ-
ent lactamases.
The motivation for the choice of antibiotics used in
this initial study was to test three different generations
of cephalosporin antibiotics. Cephalosporins are a stand-
ard treatment for skin and soft-tissue infections [58,59].
Cefazolin is the most commonly used first generation
cephalosporin. Cefoxitin is a cephamycin antibiotic, clas-
sified as a second-generation cephalosporin. The import-
ance of testing with cefoxitin is also increased because it
is routinely used as an oxacillin-surrogate routinely for
susceptibility testing [41] and MRSA phenotype predic-
tion [60-64]. Cefepime is a fourth generation cephalo-
sporin that is designed to have better stability against
β-lactamases [56,57]. Consistent with this, the β-LEAF
assay accurately identified cefepime as the most resistant
to the β-lactamase(s) in our experiments (Figure 3,
Table 4).
Interestingly, the cefazolin disk diffusion results indi-
cated all isolates as cefazolin susceptible, while analyses
from the β-LEAF assays predicted that cefazolin would
be less active for five of the isolates (#1, #6, #18, #19,
#20) (Table 2 - columns 5 and 6). At the same time, the
zone edge test applied to disk diffusion plates [55]
matched the β-lactamase prediction from both the nitro-
cefin tests and β-LEAF assay for these isolates (Table 2-
columns 2, 3 and 4). Similarly, while the E-tests
suggested isolates #1 and #6 to be cefoxitin susceptible
(and #18, #19, #20 to have different degrees of resistance
to cefoxitin) (Table 5), the β-LEAF assay predicted that
cefoxitin could be inactivated by these isolates, by virtue
of lactamase production (Figure 3). Notably, discrepan-
cies between susceptibility prediction and antibiotic effi-
cacy can occur. Conventional AST methods such as disk
diffusion and MIC determination may occasionally fail to
take resistance into account and/or misreport antibiotic
susceptibility, and special tests may be required to detect
resistance mechanisms [44-47]. Another example is that
the CLSI recommends performing tests to detect β-
lactamase production on staphylococci for which penicil-
lin zone diameters are≥29 mm or MIC≤0.12 μg/ml,
before reporting isolates as susceptible [41,42], which sug-
gests that taking β-lactamase production into consider-
ation additionally may be important. Thus, taken as a
whole, the results of the standard tests and β-LEAF are
Khan et al. BMC Microbiology 2014, 14:84 Page 10 of 14
http://www.biomedcentral.com/1471-2180/14/84consistent when considering lactamase production along
with disk diffusion or MIC results. By providing a rapid
mode to test lactamase production as well as help predict
antibiotic activity, the β-LEAF assay could prove to be ad-
vantageous and potentially minimize the need for add-
itional testing.
The overall agreement between standard CLSI recom-
mended methodologies and the proposed assay in this
work for β-lactamase detection and antibiotic activity/
susceptibility is encouraging, particularly in view of the
fact that β-LEAF assay provides these results from a
rapid (1 h) assay. When validated with a large sample
number, the assay could be adapted as a rapid diagnostic
of antibiotic susceptibility, and serve as a useful adjunct
in management of antibiotic resistance [10].
An important aspect is that in cases of high bacterial
burdens and/or heteroresistance the ‘inoculum effect’
can affect antibiotic activity [35,65-67]. Though cephalo-
sporins are used as standard treatment, they can be hy-
drolyzed by β-lactamases at high inocula (‘inoculum
effect’), resulting in clinical failures [33-40]. Conven-
tional ASTs typically utilize 5*10
5 CFU/ml as standard
test inoculums [41,42]. Koing et al. studied the efficacy
of several antibiotics against Escherichia coli and S. aur-
eus, and cited much higher bacterial numbers in
infections compared to numbers used in standard sus-
ceptibility tests as a major reason for predicted antibiotic
susceptibility not matching with observed efficacy [68].
Pus and infected peritoneal samples, for example, con-
tain an average of 2*10
8 CFU/ml, a concentration 400
times higher than the inocula used for standard conven-
tional ASTs [68]. The β-LEAF assay is compatible with
usage of high bacterial numbers (i.e. ~10
8 CFU and
higher), by virtue of which it may facilitate assessments
at clinically relevant numbers based on infection sites.
Some conventional AST methods, such as those relying
on turbidometric detection of bacterial growth, may not
be able to utilize higher bacterial numbers as the starting
inoculum.
Although PCR-based diagnostics have been employed
to detect antibiotic resistance factors relatively rapidly
[69-72], the presence of a gene does not necessarily re-
flect expression of the protein (e.g. enzyme), actually re-
sponsible for conferring resistance. For instance, Bacillus
anthracis contains genes for lactamases bla1 and bla2,
but usually resistance is not observed [73]. In the current
study also, despite the different diagnostic methodologies
for β-lactamase enzyme production being consistent
(nitrocefin disk test, zone edge test and the β-LEAF assay),
the blaZ genotype did not match for some of the isolates
(Table 2). In these isolates (e.g. #9, #15) no β-lactamase
production was observed, although they contained the
gene for β-lactamase (blaZ). Thus, investigating the pro-
tein resistance factor phenotypically can be of value. Rapid
determination of functional β-lactamase and its correl-
ation to antibiotic activity/usability by assaying for enzyme
activity is a distinctive feature of the β-LEAF assay.
Conclusions
This study reports a fluorescence quenching-dequenching
guided method for rapid β-lactamase detection and pre-
diction of antibiotic activity in the context of β-lactamase.
The initial results with standard ATCC bacterial strains
and clinical isolates are encouraging, though further valid-
ation in a large number of isolates is required. The tech-
nology merits further rigorous and broader investigations
with bacterial strains, antibiotics and direct biological
samples to be a viable routine methodology. This requires
the development of more sensitive probes and perhaps
some novel engineering, which are currently being evalu-
ated. The β-LEAF assay results are available within one
hour and in the long-term such timely assessment could
be used to guide treatment options for a particular infec-
tion, to ensure adequate therapy while avoiding unneces-
sary over- and under-prescription of antibiotics.
Because of the focus on β-lactamase, the current study
has concentrated on β-lactam based probe constructs.
However, the approach represents an optical platform
using photoactivatable constructs that can be adapted
for several targets that might confer antibiotic resistance.
An interesting area of exploration is the use of the same
technology for therapy where the constructs could be
modified to specifically target β-lactamase resistant bac-
teria [49], in a variation of photodynamic therapy [74,75]
that has shown promise in several indications of infections.
Additional files
Additional file 1: Figure S1. β-LEAF cleavage rates for ATCC control
strains and bacteria free controls. Data from the two ATCC S. aureus
control strains [known β-lactamase producer ATCC 29213 (#1) and non-
producer ATCC 25923 (#2)] and PBS only control, with three antibiotics
(cefazolin, cefoxitin and cefepime) is presented. The different samples
were incubated with β-LEAF (probe) alone or β-LEAF and respective
antibiotic, and fluorescence was monitored over 60 min. The y-axis
represents the cleavage rate of β-LEAF (measured as fluorescence change
rate – milliRFU/min) (Bacterial O.D. is not accounted for here). Results are
presented as the average of four independent experiments (each
experiment contained samples in triplicates) and error bars represent the
standard error.
Additional file 2: Figure S2. Standard Disk diffusion assay to determine
cefazolin susceptibility and zone edge test for β-lactamase detection.
Representative Disk diffusion plates for the control strains S. aureus ATCC
29213 (#1) and ATCC 25923 (#2) are shown, with the cefazolin disk at the
centre of the plate. The clear zone of inhibition and zone edges are
indicated. #1 was used as a positive control for the zone edge test (sharp
edge) and #2 as a negative control (fuzzy edge), following CLSI
guidelines.
Additional file 3: Table S1. Comparison of cefazolin disk diffusion
results for ‘standard growth’ and ‘induced growth’ bacterial cultures.
Table S2. Comparison of cefoxitin MIC results (by E-test) for ‘standard
growth’ and ‘induced growth’ bacterial cultures. Table S3. Comparison of
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growth’ bacterial cultures.
Additional file 4: Figure S3. β-lactamase induction is not necessary
prior to performing β-LEAF assays for S. aureus. β-LEAF assays were
performed with the two ATCC S. aureus control strains (positive control
#1 and negative control #2) and four S. aureus clinical isolates that
showed substantial β-lactamase production (#6, #18, #19, #20), using both
induced and un-induced growth cultures. (i) denotes ‘induced’ growth
bacteria, grown in the presence of a penicillin disk overnight to induce
and enhance β-lactamase production; (ui) denotes ‘un-induced’ bacteria,
grown on plain plates without any inducing antibiotic. The different
bacteria were incubated with β-LEAF alone and β-LEAF and cefazolin/
cefoxitin/cefepime respectively. Fluorescence was monitored over 60 min.
The y-axis represents cleavage rate of β-LEAF (measured as fluorescence
change rate – milliRFU/min) normalized by bacterial O.D. (optical density) at
600 nm. Results are presented as the average of three independent
experiments (each experiment contained samples in triplicates) and error
bars represent the standard error.
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